IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v40y2017i8d10.1007_s40264-017-0533-2.html
   My bibliography  Save this article

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis

Author

Listed:
  • Angel Y. S. Wong

    (The University of Hong Kong)

  • Esther W. Chan

    (The University of Hong Kong)

  • Shweta Anand

    (The University of Hong Kong)

  • Alan J. Worsley

    (The University of Hong Kong)

  • Ian C. K. Wong

    (The University of Hong Kong
    University College London)

Abstract

Introduction It was postulated that antibiotics including macrolides could be used for the secondary prevention of coronary heart disease but recent studies showed that macrolides increase the cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with macrolides regarding duration of effect and risk factors; and to explore the potential effect of statins for the prevention of cardiovascular events as a result of macrolide use. Methods Several electronic databases (PubMed, EMBASE, Cochrane library) were searched to identify eligible studies. Observational studies and randomized controlled trials that investigated the association between macrolides and cardiovascular events in adults aged ≥18 years were included. A meta-analysis was conducted to investigate the short- and long-term risks of cardiovascular mortality, myocardial infarction, arrhythmia, and stroke. Methodological quality was assessed by the Newcastle-Ottawa scale and the Cochrane Collaboration’s tool. The body of evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines. Results Observational studies were found to have a short-term risk of cardiovascular outcomes including cardiovascular mortality, myocardial infarction, and arrhythmia associated with macrolides but no risk was found in randomized controlled trials. However, no association for long-term risk (ranging from >30 days to >3 years) was observed in observational studies or randomized controlled trials. Limitations The included studies reported different units of denominators for absolute risk and used different outcome definitions, which might increase the heterogeneity. Conclusions More studies are required to investigate the short-term cardiovascular outcomes associated with different types of macrolides. Future studies are warranted to evaluate the effect of statins for preventing excess acute cardiovascular events associated with clarithromycin or other macrolides.

Suggested Citation

  • Angel Y. S. Wong & Esther W. Chan & Shweta Anand & Alan J. Worsley & Ian C. K. Wong, 2017. "Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis," Drug Safety, Springer, vol. 40(8), pages 663-677, August.
    • Handle: RePEc:spr:drugsa:v:40:y:2017:i:8:d:10.1007_s40264-017-0533-2
    DOI: 10.1007/s40264-017-0533-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-017-0533-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-017-0533-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ching-Hui You & Cheng-Kuan Lin & Po-Hua Chen & Suna Park & Yi-Yun Chen & Nazleen Khan & Stefania I Papatheodorou & Szu-Ta Chen, 2019. "Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:40:y:2017:i:8:d:10.1007_s40264-017-0533-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.